CHAPTERS
A seven-year healthspan opportunity: prevent the “Big Three”
The conversation opens with the claim that healthcare should aim for more years lived in good health, not just longer lifespan. Topol argues the realistic near-term win isn’t “reversing aging,” but preventing the major age-related diseases—cancer, cardiovascular disease, and Alzheimer’s—potentially yielding ~7 additional healthy years.
- •American healthcare framed as being “in crisis”
- •Shift from lifespan to healthspan as the core goal
- •Focus on preventing age-related morbidity rather than reversing aging
- •The “Big Three”: cancer, heart disease, Alzheimer’s/dementia
- •Promise of a sizeable, broadly appealing gain: ~7 more healthy years
Why “Super Agers” and why now: Wellderly findings and longevity hype
Topol explains the motivations behind writing Super Agers, including research showing “wellderly” genomes don’t explain everything and a striking patient anecdote of exceptional late-life health. He also responds to recent longevity trends where patients request interventions like rapamycin or total-body MRI, motivating an evidence-based reset.
- •Wellderly study: minimal explanatory signal found in genomes alone
- •Patient story: 98-year-old who was never sick despite family history
- •Backlash to longevity fads (e.g., rapamycin requests, total-body MRI)
- •Goal: synthesize current evidence and propose actionable blueprints
- •Need to “get the story straight” amid a flood of new longevity books
Two paths in aging science: moonshot rejuvenation vs practical prevention
Topol contrasts ambitious efforts to reverse aging (reprogramming, senolytics, major biotech bets) with a more immediate path: using aging-biology metrics to prevent specific diseases. He argues medicine has underutilized prevention despite new tools that can quantify risk earlier and more precisely.
- •“Grand slam” approach: reversing aging (mostly shown in animals)
- •Preventive approach: use aging metrics to avert disease onset
- •Medicine historically hasn’t operationalized aging science for prevention
- •Prevention targets specific outcomes: cancer, CVD, neurodegeneration
- •Opportunity: translate multi-layer aging data into clinical action
Disease incubation and the immune/inflammation common denominator
They discuss how major chronic diseases often develop over decades, providing a long runway for early detection and risk modification. Topol highlights immune dysfunction and inflammation as shared underlying threads and notes substantial preventability—especially for cardiovascular disease.
- •Big diseases often “incubate” ~20 years before diagnosis
- •Common biology: defective immune system and chronic inflammation
- •Cardiovascular disease: 80–90% preventable via modifiable factors
- •Cancer and neurodegeneration: ~50% preventable with today’s knowledge
- •Aging science adds new layers (clocks/biomarkers) to refine prevention
The five dimensions of health: AI as the integrator, then omics and more
Topol outlines his “five dimensions of health,” emphasizing AI as the key that makes the rest usable by integrating massive, multimodal data. They then expand into omics—proteomics, metabolomics, microbiome, epigenetics—moving toward a “virtual cell” understanding of human biology.
- •AI is positioned as the most important dimension for integration
- •Rise of multimodal AI (LLMs plus large reasoning models)
- •Omics beyond genetics: proteome panels, metabolome, microbiome, epigenome
- •Falling costs make deep biomarker measurement more accessible
- •Trajectory toward “virtual cell” models of biology and risk
Immune system as a controllable ‘rheostat’: cell therapies and cancer vaccines
A major section spotlights breakthroughs in immunotherapy and immune reset, including apparent cures of severe autoimmune diseases by depleting and reconstituting B cells. They also discuss personalized cancer vaccines and broader immune-modulating strategies, shifting the future toward both treating and preventing cancer.
- •Autoimmune disease breakthroughs (e.g., lupus, systemic sclerosis, MS cases) via B-cell depletion/reconstitution
- •Concept: immune system control like a “rheostat” with immunome measurement
- •Personalized tumor-protein vaccines in trials (pancreatic, kidney cancer examples)
- •Beyond checkpoint inhibitors: ADCs, tumor-infiltrating lymphocytes, other modalities
- •Vision: immune strengthening to prevent cancer, not just treat it
“Lifestyle plus”: expanding beyond diet and exercise to the exposome
Topol introduces “lifestyle plus,” arguing standard advice (diet/sleep/exercise) is necessary but insufficient. He expands the prevention lens to environmental and behavioral exposures such as air pollution, micro/nanoplastics, forever chemicals, and restorative factors like time in nature.
- •Lifestyle basics matter, but prevention requires more than the usual triad
- •Environmental burdens: air pollution, plastics (micro/nano), PFAS/forever chemicals
- •A broader exposome-oriented view of risk and resilience
- •Time in nature and other nontraditional lifestyle factors discussed
- •Lifestyle is foundational but not the only lever against the Big Three
AI for personalized forecasting: biomarkers that warn years in advance
They explore how AI could predict an individual’s health trajectory by learning from long-term records and biomarker trends. Topol uses Alzheimer’s as a flagship example, where markers like p-tau217 could provide a decade-plus early warning and be tracked over time to guide interventions.
- •AI can train on longitudinal records to predict future disease risk
- •Alzheimer’s example: p-tau217 as an early, trackable warning signal
- •Biomarkers can be monitored as gradients (not binary) to assess trend direction
- •Lifestyle can modify certain biomarker trajectories (e.g., exercise effects)
- •Core claim: without aging science + AI, this prevention paradigm isn’t feasible
Chronic disease strategy: cancer risk stratification and early detection over imaging hype
Topol argues for better cancer prevention using layered risk assessment tools like polygenic risk scores and multi-cancer early detection (MCED) tests that can detect microscopic disease. He questions the value of total-body MRI for screening given false positives and limited specificity compared with molecular early detection.
- •Polygenic risk scores as one layer for common cancer risk
- •MCED tests can detect microscopic cancer signals
- •Skepticism of total-body MRI as a broad screening tool
- •Emphasis on earlier, more precise detection paired with risk stratification
- •Goal: intervene before cancers become clinically obvious masses
GLP-1s as a historic inflection point: obesity, risk reduction, and new indications
The discussion frames GLP-1 drugs as potentially the most consequential drug class in modern medical history, not only for diabetes and obesity but for downstream disease prevention. They cover how obesity trials were delayed, how major weight loss can reduce risks across the Big Three, and the pipeline toward oral versions and broader use cases.
- •GLP-1s (e.g., Ozempic/Zepbound) described as “momentous”
- •Historical lesson: took ~20 years to realize obesity potential
- •Weight loss reduces risk of cancer, heart disease, neurodegeneration
- •Next wave: oral alternatives, lower cost, greater accessibility
- •Emerging trials/uses: Alzheimer’s prevention (non-overweight), long COVID, addiction signals
Organ clocks and proteomic aging bursts: measuring what’s aging fastest
Topol describes “organ clocks” that estimate biological aging for specific organs and can reveal which system is aging ahead of chronological age. They connect organ clocks to polygenic risk, epigenetic clocks, and high-dimensional proteomics (Olink/SomaLogic), including findings like non-linear “bursts” of aging across the lifespan.
- •Organ-specific clocks (brain/heart/immune, etc.) can show accelerated aging in one system
- •Integration with polygenic risk scores for targeted prevention plans
- •Epigenetic clocks (e.g., Horvath) as whole-body aging measures
- •Large proteomic panels (thousands of plasma proteins) enable new insights
- •Aging may occur in “bursts,” not as a purely linear process
Rebooting care delivery: from mass screening to risk-partitioned prevention
They address skepticism and institutional inertia in shifting from “sick care” to prevention. Topol critiques one-size-fits-all screening based on age alone (especially in cancer screening) and argues for Bayesian, risk-based approaches that improve outcomes while reducing waste and unnecessary procedures.
- •Clinician skepticism framed as requiring “compelling data”
- •Critique: mass screening treats everyone the same based mainly on age
- •Low yield claim: ~14% of cancers detected via current mass screening approaches
- •Risk partitioning could reduce unnecessary screening (e.g., breast cancer, colonoscopy)
- •Bayesian thinking: use measurable priors (risk layers) to personalize protocols
Best-case next decade: gradual population-level shift toward longer healthy aging
In closing, Topol describes a plausible best case where prevention is adopted widely and healthspan increases as fewer people develop the Big Three at typical ages. He emphasizes this will be a gradual trend rather than a sudden breakthrough, with some countries moving faster due to fewer structural obstacles.
- •Expected outcome: more people reaching older ages without the Big Three
- •Change will be incremental, not a “light switch” moment
- •Prevention beats cure but takes time to demonstrate benefits
- •International variation: some systems may implement faster than the U.S.
- •Goal: bend the curve toward older, healthier populations over 5–10 years
